Skip to content

Prevention of Melasma Relapse During Summertime

Prevention of Melasma Relapse During Summertime

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02061839
Enrollment
40
Registered
2014-02-13
Start date
2013-03-31
Completion date
2013-10-31
Last updated
2014-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma

Brief summary

Main objective is to show that a photoprotective sunscreen having a protection against the visible light is more effective than a sunscreen having the same UVA AND UVB protection but with a low (weak) protection against the visible, to prevent the relapses of the melasma during the summertime.

Detailed description

40 melasma affected women will be included and randomized in two parallel groups (one group protected by a UVA+UVB+visible extended sunscreen and one group group protected by a UVA+UVB sunscreen). There will be 3 visits: Baseline, T2.5months and T5months (final visit). Products application frequency: twice daily(morning and afternoon) and additional applications every 2 hours in case of solar exposure. Main evaluation criterion: the MASI score assessed from standardized photographs (system VISIA, Canfield Scientific, USA) at Baseline, middle and end of study.

Interventions

OTHERSunscream with visible light protection
OTHERSunscream

Sponsors

BIODERMA
CollaboratorUNKNOWN
Centre de Pharmacologie Clinique Applique a la Dermatologie
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Melasma

Exclusion criteria

* Other pigmentary disorders associated (including PIH)

Design outcomes

Primary

MeasureTime frameDescription
Comparison between MASI scores before prevention treatment and after 6 months6 monthsMASI scores are evaluated by two physicians blinded to the treatment received on standardized pictures taken before treatment and after 6 months of summer period

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026